Pediatric Oncology In Vivo Testing Program Coordinating Center

项目总结 NCI的儿科活体测试计划(Ped-in Vivo-TP)的首要目标是改善 儿科癌症患者与满足加速治疗和公平研究的要求 (RACE)儿童法案，以评估为儿童开发的成人靶向抗癌药物的疗效 上下文。为了协调新的Ped-in Vivo-TP计划的活动，我们组建了一个团队， 来自杰克逊实验室(JAX)和七桥基因组学(SB)的研究人员以独特的组合 在体内癌症模型、可扩展的基于云的数据管理和分析方面的专业知识和经验 系统、信息资源开发和多站点项目协调。结合互补性 JAX和SB的优势为协调中心提供了理想的基础，以最大限度地提高短期和 儿科活体试验项目对推进精准医学应用的远期影响 儿科肿瘤学。我们将管理一个全面而有凝聚力的测试计划，以提高精度 通过制药公司之间有效的公私伙伴关系在儿科肿瘤学中应用药物， 监管机构、资助者和研究机构。我们将通过以下目标实现这一目标： 目标1：建立和维护儿科活体检测协调中心(Pivot CC)，以提供 为儿科活体测试计划中的不同利益攸关方提供行政和后勤支持 财团。我们将利用我们团队几十年来在多站点计划方面的经验 管理，癌症模型开发，体内癌症模型的标准化测试，数据管理 和分析，以及信息资源开发，以确保及时决策，符合 标准协议、资源跟踪和Ped-in Vivo-TP内的有效通信。目标2： 提供数据管理、统计和生物信息学支持，以确保数据的安全性和完整性。 我们将利用JAX和SB的现有协议和软件系统来识别相关的体内癌症 模型，并收集、分析和安全管理测试中心生成的数据 财团。我们将对财团数据进行统计和生物信息学分析，以可靠地向 新型治疗药物在儿童肿瘤学环境中的疗效评估。我们将发展一种公共- 面向数据门户，以便与更广泛的科学界共享数据和方法。目标3：提供 科学协调，以保持高效和有效的临床前试验渠道。我们将抽签 从我们团队在体内药理学方面的丰富经验和类似财团的协调到 在流程的所有阶段管理和协调Ped-in Vivo-TP中心对代理的测试，从 确定相关的活体模型，以生成最终技术报告和发布结果。 我们将为财团制定、记录和跟踪绩效指标，以告知对 节目的成功和影响。

PROJECT SUMMARY The overarching goal of NCI's Pediatric In Vivo Testing Program (Ped-In Vivo-TP) is to improve outcomes of pediatric cancer patients and to satisfy the requirements of the Research to Accelerate Cures and Equity (RACE) for Children Act to assess the efficacy of targeted anti-cancer agents developed for adults in pediatric contexts. To coordinate the activities of the new Ped-In Vivo-TP initiative, we have assembled a team of investigators from The Jackson Laboratory (JAX) and Seven Bridges Genomics (SB) with unique combined expertise and experience with in vivo cancer models, scalable cloud-based data management and analysis systems, informatics resource development, and multi-site project coordination. Combining the complementary strengths of JAX and SB provides the ideal foundation for a coordinating center to maximize the short- and long-term impacts of the Pediatric In Vivo Testing Program for advancing the application of precision medicine in pediatric oncology. We will manage a comprehensive and cohesive testing program to advance precision medicine in pediatric oncology through effective public-private partnerships among pharmaceutical companies, regulatory agencies, funders, and research organizations. We will achieve this goal through the following aims: Aim 1: Establish and maintain the Pediatric In Vivo Testing Coordinating Center (PIVOT CC) to provide administrative and logistical support for diverse stakeholders in the Pediatric in Vivo Testing Program consortium. We will draw on our team's combined decades of experience with multi-site program management, cancer model development, standardized testing of in vivo cancer models, data management and analysis, and informatics resource development to ensure timely decision making, conformance to standard protocols, resource tracking, and effective communications within the Ped-In Vivo-TP. Aim 2: Provide data management, statistical, and bioinformatics support to ensure data security and integrity. We will leverage existing protocols and software systems at JAX and SB to identify relevant in vivo cancer models and to collect, analyze, and securely manage data generated from testing centers within the consortium. We will perform statistical and bioinformatic analyses on consortium data to reliably inform the evaluation of the efficacy of novel therapeutic agents in a pediatric oncology setting. We will develop a public- facing data portal for sharing of data and methods with the broader scientific community. Aim 3: Provide scientific coordination to maintain an efficient and effective preclinical testing pipeline. We will draw from the extensive experience of our team with in vivo pharmacology and coordination of similar consortia to manage and coordinate the testing of agents by the Ped-In Vivo-TP centers at all stages of the process, from the identification of relevant in vivo models to the generation of final technical reports and publication of results. We will develop, record, and track performance metrics for the consortium to inform the evaluation of the program's success and impact.